依那普利叶酸片联合肾康注射液治疗高血压肾病的临床观察
x
请在关注微信后,向客服人员索取文件
篇名: | 依那普利叶酸片联合肾康注射液治疗高血压肾病的临床观察 |
TITLE: | |
摘要: | 目的:观察依那普利叶酸片联合肾康注射液治疗高血压肾病的疗效和安全性。方法:90例高血压肾病患者随机均分为对照组和观察组。两组患者均给予抗感染、调节电解质平衡、补充氨基酸等常规治疗;在此基础上,对照组患者给予马来酸依那普利叶酸片晨起口服1片;观察组患者在对照组治疗的基础上给予肾康注射液100 ml,加入10%葡萄糖注射液300 ml中静脉滴注, 20~30滴/min,每日1次。两组患者疗程均为4周。观察两组患者的临床疗效,治疗前后肌酐清除率(Ccr)、血肌酐(Scr)、晨尿蛋白(Up)/尿肌酐(Ucr)、血清丙二醛(MDA) 、超氧化物歧化酶 (SOD) 、总抗氧化能力(T-AOC)、收缩压、舒张压及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者Ccr、SOD、T-AOC均显著高于同组治疗前,且观察组高于对照组,Scr、MDA均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);晨尿Up/Ucr、收缩压、舒张压均显著低于同组治疗前,差异均有统计学意义(P<0.05),但两组间比较差异无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,依那普利叶酸片联合肾康注射液治疗高血压肾病较单用依那普利叶酸片疗效更显著,且安全性相当。 |
ABSTRACT: | OBJECTIVE:To observe the clinical efficacy and safety of Enalapril folic acid tablet combined with Shenkang injection in the treatment of hypertensive nephropathy. METHODS:90 patients with hypertensive nephropathy were randomly divided into control group and observation group. All patients were given anti-infection, regulating electrolyte balance, supplying amino acids and other conventional treatment. Based on it, control group was orally given Maleic acid enalaprilat folic acid tablet 1 tablet in the morning, once a day; observation group was additionally given 100 ml Shenkang injection adding into 300 ml 10% Glucose injection by intravenous infusion, 20-30 drops/min, once a day. The treatment course for both groups was 4 weeks. The clinical efficacy, and clearance rate of creatinine(Ccr), serum creatinine (Scr), morning urine test urine protein (Up)/urine creatinine (Ucr), serum malondialdehyde (MDA), superoxide dismutase (SOD), total antioxidant capacity (T-AOC) before and after treatment and incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, the difference was statistically significant(P<0.05). After treatment, the Ccr, SOD and T-AOC in 2 groups were significantly higher than before, and observation group was higher than control group, Scr and MDA were significantly lower than before, and observation group was lower than control group, the differences were statistically significant(P<0.05). Morning urine test Up/Ucr, systolic blood pressure and diastolic blood pressure were significantly lower than before, and the differences were statistically significant(P<0.05), however, there was no significant difference between 2 groups(P>0.05). And there was no significant difference in the incidence of adverse reactions(P>0.05). CONCLUSIONS: Based on the conventional treatment, Enalapril folic acid tablet combined with Shenkang injection has better efficacy than only Enalapril folic acid tablet in the treatment of hypertensive nephropathy,with similar safety. |
期刊: | 2015年第26卷第36期 |
作者: | 吴立华,梁辑 |
AUTHORS: | WU Li-hua,LIANG Ji |
关键字: | 依那普利叶酸;肾康注射液;高血压肾病;疗效;安全性 |
KEYWORDS: | Enalapril folic acid; Shenkang injection; Hypertensive nephropathy; Efficacy; Safety |
阅读数: | 247 次 |
本月下载数: | 1 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!